Surfaxin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
A company’s drawn-out struggle to gain approval for a peptide therapy treating respiratory distress in preterm infants came to a…
New molecular entity: FDA approved lucinactant (Surfaxin, Discovery Laboratories) for the prevention of respiratory distress…
A company’s drawn-out struggle to gain approval for a peptide therapy treating respiratory distress in preterm infants came to a…
Respiratory distress syndrome (RDS) is a leading cause of mortality and morbidity in preterm infants. Surfactant replacement…
Background: We have published results of two randomized, controlled trials comparing lucinactant (Surfaxin®), a new generation…
Introduction: Supine sleeping is recommended to prevent sudden infant death syndrome (SIDS). Anecdotal evidence, however…
Background: Animal-derived, protein-containing surfactants perform better vs. non–protein-containing surfactants for the…
Background: Animal-derived, protein-containing surfactants perform better vs. non–protein-containing surfactants for prevention…
We performed a trial to assess the safety and tolerability of sequential bronchopulmonary segmental lavage with a dilute…